Biomarin Pharmaceutical (BMRN) Depreciation & Amortization (CF) (2009 - 2026)

Biomarin Pharmaceutical has disclosed Depreciation & Amortization (CF) across 18 years of filings, most recently posting $16.4 million for Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 25.64% year-over-year to $16.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $73.9 million (down 18.92% YoY) and the FY2025 annual result came in at $79.6 million, down 17.49% from the prior year.
• Depreciation & Amortization (CF) fell to $16.4 million in Q1 2026, from $20.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $27.4 million in Q1 2024 and troughed at $16.4 million in Q1 2026.
• A 5-year average of $23.5 million and a median of $24.8 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) advanced 9.4% — and 2025, when it fell 29.85%.
• Tracing BMRN's Depreciation & Amortization (CF) over 5 years: stood at $24.6 million in 2022, then climbed by 9.4% to $26.9 million in 2023, then dropped by 12.11% to $23.6 million in 2024, then retreated by 13.42% to $20.4 million in 2025, then decreased by 19.7% to $16.4 million in 2026.
• Business Quant data shows BMRN's Depreciation & Amortization (CF) at $16.4 million in Q1 2026, $20.4 million in Q4 2025, and $18.5 million in Q3 2025.